Aridis Pharmaceuticals Analyst Ratings
Aridis Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/06/2023 | 2062.16% | HC Wainwright & Co. | → $2 | Reiterates | Buy → Buy |
| 10/20/2023 | 2062.16% | HC Wainwright & Co. | $10 → $2 | Maintains | Buy |
| 01/26/2023 | 10710.81% | HC Wainwright & Co. | $19 → $10 | Maintains | Buy |
| 08/16/2022 | — | Maxim Group | Downgrades | Buy → Hold | |
| 07/20/2021 | 20440.54% | HC Wainwright & Co. | $11 → $19 | Maintains | Buy |
| 05/15/2020 | 11791.89% | HC Wainwright & Co. | $7 → $11 | Reiterates | → Buy |
| 02/19/2020 | 19359.46% | Roth Capital | → $18 | Initiates Coverage On | → Buy |
| 12/30/2019 | 7467.57% | HC Wainwright & Co. | → $7 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/06/2023 | 2062.16% | HC Wainwright & Co. | → 2 美元 | 重申 | 購買 → 購買 |
| 2023 年 10 月 20 日 | 2062.16% | HC Wainwright & Co. | 10 美元 → 2 美元 | 維護 | 買 |
| 01/26/2023 | 10710.81% | HC Wainwright & Co. | 19 美元 → 10 美元 | 維護 | 買 |
| 08/16/2022 | — | Maxim 集團 | 降級 | 買入 → 持有 | |
| 2021 年 7 月 20 日 | 20440.54% | HC Wainwright & Co. | 11 美元 → 19 美元 | 維護 | 買 |
| 05/15/2020 | 11791.89% | HC Wainwright & Co. | 7 美元 → 11 美元 | 重申 | → 購買 |
| 2020 年 2 月 19 日 | 19359.46% | 羅斯資本 | → 18 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2019 年 12 月 30 日 | 7467.57% | HC Wainwright & Co. | → 7 美元 | 啓動覆蓋範圍開啓 | → 購買 |
What is the target price for Aridis Pharmaceuticals (ARDS)?
Aridis Pharmicals（ARDS）的目標價格是多少？
The latest price target for Aridis Pharmaceuticals (OTCQB: ARDS) was reported by HC Wainwright & Co. on November 6, 2023. The analyst firm set a price target for $2.00 expecting ARDS to rise to within 12 months (a possible 2062.16% upside). 3 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2023年11月6日公佈了Aridis Pharmicals（場外交易代碼：ARDS）的最新目標股價。該分析公司將目標股價定爲2.00美元，預計ARDS將在12個月內升至12個月內（可能上漲2062.16％）。去年有3家分析公司公佈了評級。
What is the most recent analyst rating for Aridis Pharmaceuticals (ARDS)?
Aridis Pharmicals（ARDS）的最新分析師評級是多少？
The latest analyst rating for Aridis Pharmaceuticals (OTCQB: ARDS) was provided by HC Wainwright & Co., and Aridis Pharmaceuticals reiterated their buy rating.
HC Wainwright & Co. 對Aridis Pharmicals（場外交易代碼：ARDS）的最新分析師評級由HC Wainwright & Co. 提供，阿里迪斯製藥重申了買入評級。
When is the next analyst rating going to be posted or updated for Aridis Pharmaceuticals (ARDS)?
Aridis Pharmicals（ARDS）的下一份分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aridis Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aridis Pharmaceuticals was filed on November 6, 2023 so you should expect the next rating to be made available sometime around November 6, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Aridis Pharmicals的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。Aridis Pharmicals的最新評級是在2023年11月6日公佈的，因此您應該預計下一個評級將在2024年11月6日左右公佈。
Is the Analyst Rating Aridis Pharmaceuticals (ARDS) correct?
Aridis Pharmicals（ARDS）的分析師評級是否正確
While ratings are subjective and will change, the latest Aridis Pharmaceuticals (ARDS) rating was a reiterated with a price target of $0.00 to $2.00. The current price Aridis Pharmaceuticals (ARDS) is trading at is $0.09, which is within the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但Aridis Pharmicals（ARDS）的最新評級得到了重申，目標股價爲0.00美元至2.00美元。Aridis Pharmicals（ARDS）目前的交易價格爲0.09美元，在分析師的預測區間內。
譯文內容由第三人軟體翻譯。